ArticleDiscover oncology2026
Risk-dependent conditional survival analysis and annual hazard rate of primary ocular adnexal lymphoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe real-time prognosis of patients with primary ocular adnexal lymphoma (POAL) who have survived for several years remains uncertain. Our objective was to assess survival dynamics over time in POAL using conditional survival (CS) analysis and annual hazard functions.
methodsWe utilized data from the SEER database (2004–2019) to conduct CS analysis on POAL patients. A total of 1901 patients were included. CS was estimated using the Kaplan–Meier method, and the annual hazard rate (AHR) was calculated to examine changes in mortality risk over time. A predictive nomogram incorporating CS analysis was developed using a random survival forest (RSF) approach, with model performance evaluated through calibration, concordance index (C-index), receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).
resultsCS analysis revealed a significant improvement in survival over time, with 10-year CS rates increasing from 69% at diagnosis to over 96% for patients surviving 1–9 years. The AHR peaked at 4.1% in the first year, declining progressively to 1.7% by year 10. The RSF algorithm identified five key prognostic factors—age, tumor site, histology, tumor stage, and radiotherapy—as important predictors. A CS-based nomogram was developed, and its reliability was further confirmed through calibration curves, C-index values, and ROC analysis, with AUC values exceeding 0.80 for 3-, 5-, and 10-year survival predictions.
conclusionsThis study outlined the changes in CS prognosis and AHR for patients with POAL. Furthermore, we developed a CS-based nomogram using SEER data, which effectively integrated dynamic survival improvements and time-dependent risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.